Study S000157

Glutide for Ending Methamphetamine

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07204249
Acronym: GEM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 162
Start: 2026-02-26
Primary completion: 2030-02-15
Lead sponsor: San Francisco Department of Public Health
Conditions: Methamphetamine-dependence
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Ratio of eligible to enrolled participants [14 months]
Proportion of on-time injections [20 months]
Past month methamphetamine use at baseline vs. week 12 [12 weeks]
Rate of study-drug discontinuation [12 weeks]
Reduced methamphetamine use [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.